HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
SuspendedNCT04640636

IM Ketamine vs Midazolam for Suicidal ER Patients

Medication studyAges 18–65United StatesSuicide prevention
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 9, 2021
Recruitment status
Suspended
Enrollment listed in the registry
90
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04640636
Official title
Show the full official title

IM Ketamine vs Midazolam for Suicidal ER Patients

Recruitment & locations

Suspended

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Ketamine hydrochloride injection and Midazolam injection.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as suspended.

Want to explore more studies?

Explore studies